HomeCompareCCMP vs ABBV

CCMP vs ABBV: Dividend Comparison 2026

CCMP yields 13.47% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCMP wins by $3353054.80M in total portfolio value
10 years
CCMP
CCMP
● Live price
13.47%
Share price
$173.69
Annual div
$23.40
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3353054.91M
Annual income
$3,305,915,027,308.01
Full CCMP calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CCMP vs ABBV

📍 CCMP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCMPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCMP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCMP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCMP
Annual income on $10K today (after 15% tax)
$1,145.14/yr
After 10yr DRIP, annual income (after tax)
$2,810,027,773,211.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, CCMP beats the other by $2,810,027,751,344.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCMP + ABBV for your $10,000?

CCMP: 50%ABBV: 50%
100% ABBV50/50100% CCMP
Portfolio after 10yr
$1676527.51M
Annual income
$1,652,957,526,516.86/yr
Blended yield
98.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CCMP
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCMP buys
0
ABBV buys
0
No recent congressional trades found for CCMP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCMPABBV
Forward yield13.47%3.12%
Annual dividend / share$23.40$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$3353054.91M$104.7K
Annual income after 10y$3,305,915,027,308.01$25,725.73
Total dividends collected$3349892.52M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCMP vs ABBV ($10,000, DRIP)

YearCCMP PortfolioCCMP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,394$2,694.46$11,559$438.51+$1.8KCCMP
2$21,078$6,745.94$13,494$640.86+$7.6KCCMP
3$42,396$19,842.34$15,951$945.97+$26.4KCCMP
4$119,962$74,598.94$19,152$1,413.89+$100.8KCCMP
5$522,909$394,549.27$23,443$2,146.38+$499.5KCCMP
6$3,774,123$3,214,610.22$29,391$3,321.96+$3.74MCCMP
7$47,405,812$43,367,500.22$37,948$5,265.87+$47.37MCCMP
8$1,068,907,945$1,018,183,726.54$50,795$8,596.74+$1068.86MCCMP
9$44,055,961,799$42,912,230,297.28$71,034$14,549.41+$44055.89MCCMP
10$3,353,054,906,432$3,305,915,027,308.01$104,715$25,725.73+$3353054.80MCCMP

CCMP vs ABBV: Complete Analysis 2026

CCMPStock

CMC Materials, Inc., together with its subsidiaries, provides consumable materials to semiconductor manufacturers, and pipeline and adjacent industry customers in North America, Asia, Europe, the Middle East, Africa, and South America. The company operates in two segments, Electronic Materials and Performance Materials. The Electronic Materials segment develops, produces, and sells chemical mechanical planarization (CMP) slurries for polishing various materials used in IC devices, including tungsten, dielectric materials, copper, tantalum, and aluminum; and various materials that are used in the production of disk substrates and magnetic heads for hard disk drives; and CMP pads, which are used in conjunction with slurries in the CMP process. This segment also offers sulfuric, phosphoric, nitric, and hydrofluoric acids, as well as ammonium hydroxide, hydrogen peroxide, isopropyl alcohol, other specialty organic solvents, and various blends of chemicals; and develops and manufactures consumable products for cleaning advanced probe cards and test sockets. The Performance Materials segment provides pipeline and industrial materials comprising polymer-based drag-reducing agents for crude oil transmission, valve greases, cleaners and sealants, and related services and equipment; and routine and emergency maintenance services, as well as training services. This segment also offers precision polishing and metrology systems for advanced optics applications; and magneto-rheological polishing fluids, consumables, and spare and replacement parts, as well as optical polishing services and other customer support services; and engages in the wood treatment business. The company was formerly known as Cabot Microelectronics Corporation and changed its name to CMC Materials, Inc. in October 2020. CMC Materials, Inc. was incorporated in 1999 and is headquartered in Aurora, Illinois.

Full CCMP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CCMP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCMP vs SCHDCCMP vs JEPICCMP vs OCCMP vs KOCCMP vs MAINCCMP vs JNJCCMP vs MRKCCMP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.